Novel treatments for attention-deficit / hyperactivity disorder
Patent Information
- Application Number
- JP2023528637
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-03-11
- Filing Date
- 2021-11-12
- Publication Date
- 2024-11-19
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current treatments for attention-deficit/hyperactivity disorder (ADHD) are limited in efficacy and associated with adverse effects, necessitating the development of alternative therapies that provide clinical benefit with good tolerability.
Compounds according to formula (I) are administered to treat or prevent ADHD, shown to reduce hyperactivity and motor impulsivity in zebrafish models and ameliorate cognitive deficits in mice, without affecting sleep parameters.
The compounds effectively reduce ADHD symptoms such as hyperactivity and cognitive impairments without causing sleep disturbances, offering a more tolerable treatment option compared to existing medications.
Smart Images

Figure 00000000_0000_ABST
Abstract
Description
[Technical Field]
[0001] The present invention relates to the treatment and / or prevention of attention-deficit / hyperactivity disorder (ADHD). The present invention also relates to dosing regimens and kits that find utility in the treatment and / or prevention of ADHD. [Background technology]
[0002] Attention-deficit / hyperactivity disorder (ADHD) is characterized by impairments in attention, hyperactivity, or impulsivity, or a combination thereof. The condition affects approximately 5% of individuals under the age of 18 worldwide, and approximately 65% of cases persist into adulthood. The prevalence of ADHD in adults is estimated to be approximately 2.5% worldwide (Non-Patent Document 1).
[0003] The etiology of ADHD is complex and not fully understood. However, impaired dopaminergic neurotransmission is thought to be a common feature of ADHD patients. Recent studies have also found that genetic mutations in the Latrophilin 3 (LPHN3, also known as ADGRL3) gene are strongly associated with ADHD (Non-Patent Document 2). Further studies in zebrafish have shown that downregulation of latrophilin3.1 (lphn3.1), a zebrafish LPHN3 homolog, causes hyperactivity (Non-Patent Document 3 and Non-Patent Document 4). These studies also suggest that downregulation of lphn3.1 is associated with abnormal dopaminergic neurotransmission.
[0004] Established treatments for ADHD include pharmacological treatments such as psychostimulants (e.g., methylphenidate, dexamphetamine, and lisdexamphetamine), norepinephrine reuptake inhibitors (e.g., atomoxetine), and α2-adrenergic agonists (e.g., guanfacine and clonidine).Treatment of ADHD can also include the use of non-pharmacological therapies, either as monotherapy or in combination with pharmacological treatments.Examples of non-pharmacological treatments that may be beneficial for patients with ADHD include cognitive behavioral therapy (CBT), dietary treatments (e.g., elimination of supplemental fatty acids and artificial food dyes), and exercise programs.
[0005] Clinical guidelines, such as the UK National Institute for Health and Care Excellence (NICE) guidelines, recommend the use of methylphenidate, atomoxetine, and dexamphetamine for the treatment of ADHD in children or adolescents, and lisdexamfetamine or methylphenidate for the treatment of ADHD in adults. However, despite the approved use of such treatments for ADHD, they remain controversial due to their limited efficacy and / or adverse effects (Non-Patent Document 5). [Prior art documents] [Non-patent literature]
[0006] [Non-Patent Document 1] Thapar & Cooper,The Lancet,2016,387(10024),1240-1250 [Non-patent document 2] Arcos-Burgos et al.,2010,Molecular Psychiatry,15,1053-1066 [Non-patent document 3] Lange et al.Mol Psychiatry 2012,17,946-954 [Non-patent document 4] Lange et al.,2018,Prog Neuropsychopharm Biol Psych,84,181-189 [Non-Patent Document 5] Cortese et al.,2018,The Lancet,Psychiatry,5(9),727-738 Summary of the Invention [Problem to be solved by the invention]
[0007] Thus, there remains a need for additional treatments for ADHD that provide clinical benefit while being well clinically tolerated. [Means for solving the problem]
[0008] The present invention provides a compound according to formula (I) for use in the treatment or prevention of attention deficit / hyperactivity disorder (ADHD):
[0009] [ka] (In the formula, R 1 , R 2 , and R 3 are independently H, halogen, C 1~4 Alkyl, C 1~4 Alkylthio-, C 1~4 alkyloxy- and 3- to 5-membered non-aromatic carbocyclic rings, wherein the carbocyclic rings are selected from one or more C 1~4 optionally substituted with alkyl; R 4 H, C(O)H and C(O)C 1~4 alkyl, However, R 1 , R 2 , R 3 , and R 4 But not all of them are H) or a tautomer thereof, or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutically acceptable salt or solvate of the tautomer thereof.
[0010] The present invention further provides a method for the treatment or prevention of ADHD, comprising the step of administering a dose of a compound of formula (I) to a patient known to have, suspected to have, or at risk of developing ADHD.
[0011] The present inventors have found that in a zebrafish (Danio rerio) model of ADHD, the compound of formula (I) is surprisingly effective in reducing ADHD symptoms, such as hyperactivity and motor impulsivity, in Lphn3.1 knockout zebrafish larvae. The present inventors have also found that in a scopolamine-induced cognitive dysfunction model in mice, the compound of formula (I) is surprisingly effective in improving cognitive impairments associated with ADHD, such as impaired attention and working memory. The present inventors have also found that the compound of formula (I) is significantly effective in reducing ADHD symptoms without affecting sleep parameters, such as sleep fragmentation, sleep ratio, sleep rate, duration of wakefulness episodes, and duration of sleep episodes.
[0012] The present invention also provides the use of a compound according to formula (I) for the manufacture of a medicament for the treatment and / or prevention of ADHD.
[0013] The present invention further provides a kit comprising a compound according to formula (I), one or more additional pharmacological interventions, and instructions for dietary intervention and / or instructions for psychological intervention. The kit of the present invention finds use in the treatment or prevention of ADHD. [Brief explanation of the drawings]
[0014] [Figure 1]2 shows spectrograms of 24-hour recordings of velocity (mm / sec) of zebrafish larvae with a homozygous knockout of the Lphn3.1 gene (referred to herein as "Lphn3.1 HOM") and zebrafish larvae with a wild-type Lphn3.1 gene (referred to herein as "Lphn3.1 WT"). Both groups of larvae were administered a vehicle control (i.e., DMSO without test compound). The gray area shown in the spectrogram indicates the light-off phase of the experiment (five 30-minute phases, the first of which began at 1:30 PM, followed by a 10-hour, lights-off night period beginning at 10 PM and ending at 8 AM the next morning). [Figure 2] A bar graph showing the difference in the average distance traveled by Lphn3.1 HOM and Lphn3.1 WT larvae during the five 30-minute light-on phases is shown. No significant interaction between genotype and vehicle (i.e., DMSO) was observed (f = 1,003, df = 1, p = 0.317). A significant effect of genotype on distance traveled was observed between Lphn3.1 HOM and Lphn3.1 WT larvae (f = 117.67, df = 1, p < 0.001). A non-significant effect of vehicle was observed between naive (i.e., larvae that received neither test compound nor vehicle control) and DMSO-treated larvae (f = 0,222 df = 1, p = 0.638). [Figure 3]Figure 3 shows a comparison of the distance traveled by Lphn3.1 HOM larvae receiving moxonidine, atomoxetine (referred to as tomoxetine hydrochloride in Figure 3), or vehicle control (i.e., DMSO). The dashed line on the plot indicates the average distance traveled by Lphn3.1 HOM larvae over five light phases after treatment with vehicle control (n = 189). The dotted line indicates the average distance traveled by Lphn3.1 HOM larvae over five light phases after treatment with 1 μM atomoxetine hydrochloride (n = 24). The dots indicate the effect of moxonidine at dosages of 1 μM, 10 μM, or 30 μM on the average distance traveled by Lphn3.1 HOM larvae over five light phases (n = 24) (all data shown ± SEM). A statistically significant difference was observed between larvae treated with moxonidine and those receiving the vehicle control (f=37,276, df=3, p<0.001; second round: f=39,637, df=3, p<0.001). [Figure 4] Figure 1 shows the percentage of spontaneous alternation in mice in the T-maze assay after exposure to scopolamine and treatment with donepezil, atomoxetine, moxonidine, or saline. Data are expressed as the mean ± SEM of n = 10 mice per experimental group. ***P < 0.001 = significantly different from vehicle / scopolamine mice compared to vehicle / saline mice (one-way ANOVA with Dunnett's post-hoc test). [Figure 5]Figure 1 shows spectrograms of 24-hour recordings of velocity (mm / sec) of zebrafish larvae with a homozygous knockout of the Lphn3.1 gene (referred to herein as "Lphn3.1 HOM") and zebrafish larvae with a wild-type Lphn3.1 gene (referred to herein as "Lphn3.1 WT"). Both groups of larvae were administered 10 μM moxonidine. The treated Lphn3.1 WT group is referred to as "WT 10 μM" in the figure, and the treated Lphn3.1 HOM group is referred to as "HOM 10 μM" in the figure. The Lphn3.1 HOM group treated with vehicle only (i.e., DMSO without test compound) is referred to as "HOM DMSO" in the figure. The grey area shown in the spectrogram indicates the lights-out phases of the experiment (five 30-minute phases, the first of which began at 1:30 PM, followed by a 10-hour lights-out night period beginning at 10 PM and ending at 8 AM the next morning). [Figure 6A] Figure 1 shows the effects of 1 μM, 10 μM, or 30 μM moxonidine on sleep fragmentation, sleep ratio, rate during sleep, duration of wake episodes, and duration of sleep episodes in zebrafish. Data points shown in these figures are included in Tables 1A-1D. [Figure 6B]
[0033] Figure 1 shows the effects of 1 μM, 10 μM, or 30 μM clonidine on sleep fragmentation, sleep ratio, rate during sleep, duration of wake episodes, and duration of sleep episodes in zebrafish. The data points shown in these figures are included in Tables 1A-1D. [Figure 6C]
[0033] Figure 1 shows the effects of 1 μM, 10 μM, or 30 μM atomoxetine on sleep fragmentation, sleep ratio, rate during sleep, duration of wake episodes, and duration of sleep episodes in zebrafish. Data points shown in these figures are included in Tables 1A-1D. [Figure 6D] Figure 1 shows the effects of 1 μM, 10 μM, or 30 μM guanfacine on sleep fragmentation, sleep ratio, rate during sleep, duration of wake episodes, and duration of sleep episodes in zebrafish. Data points shown in these figures are included in Tables 1A-1D. [Figure 7] Figure 7 shows a comparison of the distance traveled by Lphn3.1 HOM larvae receiving a known, highly selective I1-imidazoline receptor agonist, atomoxetine (referred to as tomoxetine hydrochloride in Figure 7), or vehicle control (i.e., DMSO). The dashed line on the plot indicates the average distance traveled by Lphn3.1 HOM larvae over five light phases after treatment with vehicle control (n = 189). The dotted line indicates the average distance traveled by Lphn3.1 HOM larvae over five light phases after treatment with 1 μM atomoxetine hydrochloride (n = 24). Points show the effect of known I1-imidazoline receptor agonists at doses of 0, 1, 1, 10, 30, or 100 μM on the average distance traveled by Lphn3.1 HOM larvae over five light-on phases (first round: n = 24, second round: n = 72) (all data shown ± SEM). A statistically significant difference was observed between larvae treated with I1-imidazoline receptor agonists and those receiving the vehicle control (F(5,132) = 21.33, df = 5, p < 0.001; second round: F(3,276) = 44.40, df = 3, p < 0.001). DETAILED DESCRIPTION OF THE INVENTION
[0015] The inventors of the present invention have found that compounds according to formula (I) are surprisingly effective in treating or preventing ADHD.
[0016] As discussed in more detail below, the present inventors have found that moxonidine is surprisingly effective in reducing activity in zebrafish larvae in a model of ADHD. The ADHD model used by the present inventors uses zebrafish carrying a homozygous knockout of the Latrophilin 3 (lphn.3.1) gene. Mutations in the corresponding lphn.3.1 gene in humans (i.e., LPHN3) have been strongly implicated as a risk factor for ADHD in humans (Arcos-Burgos et al., 2010, Mol Psychiatry 15, 1053-1066, and Lange et al., Prog Neuropsychopharmacol Biol Psychiatry, 2018, 84(A), 181-189). The function of the lphn.3.1 gene in zebrafish has been found to correlate with that observed in humans. In the zebrafish model used by the present inventors, ADHD-like behavioral phenotypes (e.g., hyperactivity and motor impulsivity) are observed in zebrafish larvae carrying a homozygous knockout of the lphn3.1 gene. Using this zebrafish model of ADHD, the present inventors have determined that moxonidine is surprisingly effective in reducing ADHD behaviors, such as hyperactivity and motor impulsivity. The present inventors have also found that moxonidine is effective in restoring cognitive function in a scopolamine-induced cognitive impairment model in mice. Because ADHD can manifest itself as cognitive impairment, such as declines in attention and working memory, these data further demonstrate the efficacy of moxonidine in reducing ADHD symptoms.
[0017] Compounds that are structurally similar to moxonidine or that differ by minor structural variations are expected to exhibit similar properties to moxonidine in the ADHD models described herein.
[0018] Thus, the present invention provides a compound according to formula (I) for use in the treatment or prevention of ADHD.
[0019] [ka] or a tautomer thereof, or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutically acceptable salt or solvate of the tautomer thereof.
[0020] In the compounds of formula (I), R 1 , R 2 , and R 3 are independently hydrogen, halogen, C 1~4 Alkyl, C 1~4 Alkylthio-, C 1~4 alkyloxy-, and 3- to 5-membered non-aromatic carbocyclic rings, wherein the carbocyclic rings may be selected from one or more C 1~4 Optionally substituted with alkyl. For example, R 1 , R 2 , and R 3 may each independently be hydrogen, F, Cl, Br and I, methyl, ethyl, -SCH3, -SCH2CH3, methoxy, ethoxy, cyclopropyl, cyclobutyl, or cyclopentyl. 1 , R 2 , and R 3 are each independently hydrogen, F, Cl, methyl, —SCH3, methoxy or ethoxy. More preferably, R 1 , R 2 , and R 3 are each independently F, Cl, methyl, ethyl, methoxy, or ethoxy. For example, R 1 may be methoxy or ethoxy, R 2 may be F or Cl, R 3 may be methyl or ethyl.
[0021] In the compounds of formula (I), R 4 are hydrogen, C(O)H and C(O)C 1~4 For example, R4 may be hydrogen, C(O)H, C(O)CH3, or C(O)CH2CH3. Preferably, R 4 is hydrogen, C(O)H or C(O)CH. More preferably, R4 is hydrogen.
[0022] In the compounds of formula (I), R 1 , R 2 , R 3 , and R 4 is not all hydrogen. For example, R 1 , R 2 , R 3 , and R 4 are each independently a halogen, C 1~4 Alkyl, C 1~4 Alkylthio-, C 1~4 alkyloxy-, or a 3- to 5-membered non-aromatic carbocyclic ring, wherein the carbocyclic ring is selected from the group consisting of one or more C 1~4 or, for example, R 1 is a halogen, C 1~4 Alkyl, C 1~4 Alkylthio-, C 1~4 alkyloxy-, or a 3- to 5-membered non-aromatic carbocyclic ring, wherein the carbocyclic ring is selected from the group consisting of one or more C 1~4 optionally substituted with alkyl, R 2 , R 3 , and R 4 are each independently hydrogen, halogen, or C 1~4 Alkyl, C 1~4 Alkylthio-, C 1~4 alkyloxy-, or a 3- to 5-membered non-aromatic carbocyclic ring, wherein the carbocyclic ring is selected from the group consisting of one or more C 1~4 or, for example, R 2 is a halogen, C 1~4 Alkyl, C 1~4 Alkylthio-, C 1~4 alkyloxy-, or a 3- to 5-membered non-aromatic carbocyclic ring, wherein the carbocyclic ring is selected from the group consisting of one or more C 1~4 optionally substituted with alkyl, R 1 , R 3 , and R 4 are each independently hydrogen, halogen, or C 1~4 Alkyl, C 1~4 Alkylthio-, C 1~4alkyloxy-, or a 3- to 5-membered non-aromatic carbocyclic ring, wherein the carbocyclic ring is selected from the group consisting of one or more C 1~4 or, for example, R 3 is a halogen, C 1~4 Alkyl, C 1~4 Alkylthio-, C 1~4 alkyloxy-, or a 3- to 5-membered non-aromatic carbocyclic ring, wherein the carbocyclic ring is selected from the group consisting of one or more C 1~4 optionally substituted with alkyl, R 1 , R 2 , and R 4 are each independently hydrogen, halogen, or C 1~4 Alkyl, C 1~4 Alkylthio-, C 1~4 alkyloxy-, or a 3- to 5-membered non-aromatic carbocyclic ring, wherein the carbocyclic ring is selected from the group consisting of one or more C 1~4 or, for example, R 4 is a halogen, C 1~4 Alkyl, C 1~4 Alkylthio-, C 1~4 alkyloxy-, or a 3- to 5-membered non-aromatic carbocyclic ring, wherein the carbocyclic ring is selected from the group consisting of one or more C 1~4 optionally substituted with alkyl, R 1 , R 2 , and R 3 are each independently hydrogen, halogen, or C 1~4 Alkyl, C 1~4 Alkylthio-, C 1~4 alkyloxy-, and 3- to 5-membered non-aromatic carbocyclic rings, wherein the carbocyclic rings may be selected from one or more C 1~4 Optionally substituted with alkyl.
[0023] Preferably, in the compounds of formula (I), R 1 and R 2 are each independently a halogen, C 1~4 Alkyl, C 1~4 Alkylthio-, C 1~4 alkyloxy- or a 3- to 5-membered non-aromatic carbocyclic ring, wherein the carbocyclic ring is one or more C 1~4optionally substituted with alkyl, R 3 and R 4 are each independently hydrogen, halogen, or C 1~4 Alkyl, C 1~4 Alkylthio-, C 1~4 alkyloxy- or a 3- to 5-membered non-aromatic carbocyclic ring, wherein the carbocyclic ring is one or more C 1~4 For example, in the compound of formula (I), R 1 may be halogen, R 2 is C 1~4 Alkyl, C 1~4 Alkylthio-, C 1~4 alkyloxy-, or a 3- to 5-membered non-aromatic carbocyclic ring, wherein the carbocyclic ring is selected from the group consisting of one or more C 1~4 optionally substituted with alkyl, R 3 and R 4 are each independently hydrogen, halogen, or C 1~4 Alkyl, C 1~4 Alkylthio-, C 1~4 alkyloxy-, or a 3- to 5-membered non-aromatic carbocyclic ring, wherein the carbocyclic ring is selected from the group consisting of one or more C 1~4 or, for example, R 1 is C 1~4 Alkyl, C 1~4 Alkylthio-, C 1~4 alkyloxy-, or a 3- to 5-membered non-aromatic carbocyclic ring, wherein the carbocyclic ring is selected from the group consisting of one or more C 1~4 optionally substituted with alkyl, R 2 may be halogen, R 3 and R 4 are each independently hydrogen, halogen, or C 1~4 Alkyl, C 1~4 Alkylthio-, C 1~4 alkyloxy-, or a 3- to 5-membered non-aromatic carbocyclic ring, wherein the carbocyclic ring is selected from the group consisting of one or more C 1~4 or, for example, R 1 and R 2 are hydrogen (e.g., R 1 and R 2are each independently F, Cl, Br, or I, and R 3 and R 4 are independently hydrogen, halogen, C 1~4 Alkyl, C 1~4 Alkylthio-, C 1~4 alkyloxy- and 3- to 5-membered non-aromatic carbocyclic rings, wherein the carbocyclic rings are selected from one or more C 1~4 Optionally substituted with alkyl.
[0024] Preferably, R 1 is C 1~4 Alkyl, C 1~4 Alkylthio-, C 1~4 alkyloxy- or a 3- to 5-membered non-aromatic carbocyclic ring, wherein the carbocyclic ring is one or more C 1~4 optionally substituted with alkyl, R 2 is a halogen and R 3 and R 4 are each independently hydrogen, halogen, or C 1~4 Alkyl, C 1~4 Alkylthio-, C 1~4 alkyloxy- and 3- to 5-membered non-aromatic carbocyclic rings, wherein the carbocyclic rings are each selected from the group consisting of one or more C 1~4 More preferably, R 1 is methoxy or ethoxy, and R 2 is F or Cl, and R 3 and R 4 are each independently hydrogen, methyl or ethyl. Even more preferably, R 1 is methoxy or ethoxy, and R 2 is F or Cl, and R 3 is methyl or ethyl, and R 4 is hydrogen, e.g., R 1 may be methoxy, and R 2 may be F or Cl, R 3 may be methyl, R 4 is H.
[0025] In a preferred embodiment, the compound of formula (I) is a compound of formula (Ia)
[0026] [ka] or a tautomer thereof, or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutically acceptable salt or solvate of the tautomer thereof. The present inventors have found that the compound of formula (Ia) (i.e., moxonidine) is particularly effective in reducing ADHD behaviors, such as hyperactivity and motor impulsivity, in a zebrafish model of ADHD. The present inventors have also shown that the compound of formula (Ia) is surprisingly effective in improving cognitive impairment associated with ADHD using a scopolamine-induced cognitive impairment model in mice, and that the compound of formula (Ia) does not affect sleep parameters, such as sleep fragmentation, sleep ratio, sleep speed, duration of wakefulness episodes, and duration of sleep episodes.
[0027] Moxonidine is known to be a highly selective agonist of the I1-imidazoline receptor. Without wishing to be bound by any one theory, the inventors believe that the high selectivity of moxonidine for the I1-imidazoline receptor provides an effective treatment for ADHD while reducing off-target effects, thus making moxonidine a more tolerable treatment for ADHD compared to established treatments.
[0028] For the avoidance of doubt, in this document references to compounds of formula (I) are intended to include all tautomeric forms, salts and solvates thereof, unless otherwise stated.
[0029] The compounds for use according to the present invention may be prepared using methods known to those skilled in the art of organic chemistry, and specific methods for preparing specific compounds according to the present invention are known in the art.For example, as described in US 4,323,570, which is incorporated herein by reference, various compounds for use according to the present invention can be prepared by reacting a suitable 5-aminopyrimidine with a suitable 2-imidazolidinone.One specific method for preparing the compound of formula (I) described in US 4,323,570 includes reacting a suitable 5-aminopyrimidine with a suitable 2-imidazolidinone in the presence of a dehydrating agent such as phosphoryl chloride (POCl).Suitable 5-aminopyrimidines and 2-imidazolidinones are readily available using methods known in the art and can often be obtained as starting materials from commercially available sources.
[0030] Pharmaceutical preparations of compounds of formula (Ia) suitable for use in the present invention are available from commercial sources.For example, pharmaceutical preparations of compounds of formula (Ia) are marketed under the name PHYSIOTENS®.Generic pharmaceutical preparations of compounds of formula (Ia) are also available.
[0031] Depending on the substituents present in the compound of formula (I), the compound may form salts or solvates. Salts of compounds of formula (I) suitable for use in the present invention are those in which the counterion is pharmaceutically acceptable. However, salts having non-pharmaceutically acceptable counterions are within the scope of the present invention, for example, for use as intermediates in the preparation of compounds of formula (I) and their pharmaceutically acceptable salts and physiologically functional derivatives. Salts suitable for use in accordance with the present invention include those formed with organic or inorganic acids. Specifically, suitable salts formed with acids in accordance with the present invention include salts formed with mineral acids, strong organic carboxylic acids such as alkanecarboxylic acids of 1 to 4 carbon atoms that are unsubstituted or substituted (e.g., by halogen), e.g., saturated or unsaturated dicarboxylic acids, e.g., hydroxycarboxylic acids, e.g., amino acids, or organic sulfonic acids, e.g., unsubstituted or substituted (e.g., by halogen) (C1-C4)-alkyl- or aryl-sulfonic acids. Pharmaceutically acceptable acid addition salts include those formed from hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, citric acid, tartaric acid, acetic acid, phosphoric acid, lactic acid, pyruvic acid, acetic acid, trifluoroacetic acid, succinic acid, perchloric acid, fumaric acid, maleic acid, glycolic acid, lactic acid, salicylic acid, oxalic acid, oxaloacetic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, formic acid, benzoic acid, malonic acid, naphthalene-2-sulfonic acid, benzenesulfonic acid, isethionic acid, ascorbic acid, malic acid, phthalic acid, aspartic acid, and glutamic acid, lysine, and arginine acid. Suitable cations that may be present in the salt include alkali metal cations, particularly sodium, potassium, and calcium, as well as ammonium or amino cations.
[0032] Those skilled in the art of organic chemistry will recognize that many organic compounds form complexes with solvents with which they react or from which they may precipitate or crystallize. These complexes are known as "solvates." For example, a complex with water is known as a "hydrate." The complex may incorporate the solvent in stoichiometric or non-stoichiometric amounts. Solvates are also known as Water-Insoluble Drug Formulations, 2 nd ed. R. Lui CRC Press, page 553, and Byrn et al. Pharm Res 12(7), 1995, 945-954. Before being put into solution, the compound of formula (I) may be in the form of a solvate. Solvates of the compound of formula (I) suitable for use as a pharmaceutical according to the present invention are solvates in which the associated solvent is pharmaceutically acceptable. For example, hydrates are pharmaceutically acceptable solvates.
[0033] A compound that can be converted into a compound of formula (I) or its active metabolite or residue upon administration to a recipient is known as a "prodrug." Thus, in certain embodiments, a compound of formula (I) can be provided in the form of a prodrug. A prodrug can be converted into its active form, which has medical effects, for example, by hydrolysis in the body, for example, in the blood. Pharmaceutically acceptable prodrugs are described in T. Higuchi and V. Stella, Prodrugs as Novel Delivery Systems, Vol. 14 of the ACS Symposium Series (1976); "Design of Prodrugs" ed. H. Bundgaard, Elsevier, 1985, and Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987, which are incorporated herein by reference.
[0034] Pharmaceutical Compositions Although it is possible for the compound of formula (I) to be administered alone, it is preferred that it be present in a composition, particularly a pharmaceutical composition. The pharmaceutical composition of the present invention comprises a compound of formula (I) and one or more pharmaceutically acceptable excipients.
[0035] Pharmaceutical compositions include those suitable for oral, parenteral (including subcutaneous, intradermal, intraosseous injection, intramuscular, intravascular (bolus or infusion), and intramedullary), intraperitoneal, transmucosal, transdermal, rectal, and topical (including cutaneous, buccal, sublingual, and ocular) administration, although the most suitable route may depend on the characteristics of the subject being treated, such as race, age, weight, sex, medical condition, the particular type of ADHD (e.g., "impulsive / hyperactive," "inattentive," and "combined" ADHD) and its severity, and other relevant medical and physical factors.
[0036] Preparations for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain antioxidants, buffers, bacteriostats, and solutes that render the preparation isotonic with the blood of the intended recipient, as well as aqueous and non-aqueous sterile suspensions which may contain suspending agents and thickening agents. The preparations may be presented in unit-dose or multi-dose containers, for example, sealed ampoules and vials, and can be stored in a freeze-dried (lyophilized) condition requiring only the addition of a sterile liquid carrier (e.g., physiological saline or water for injection) immediately prior to use. Extemporaneous injection solutions and suspensions can be prepared from sterile powders, granules, and tablets of the kind previously described. Exemplary compositions for parenteral administration include injectable solutions or suspensions, which may contain, for example, a suitable non-toxic parenterally-acceptable diluent or solvent (e.g., mannitol, 1,3-butanediol, water, Ringer's solution, isotonic sodium chloride solution) or other suitable dispersing or wetting agents and suspending agents (including synthetic mono- or diglycerides), and fatty acids (including oleic acid), or Cremaphor.
[0037] Compositions for nasal, aerosol, or inhalation administration include solutions in saline, which may contain, for example, benzyl alcohol or other suitable preservatives, absorption enhancers to enhance bioavailability, and / or other solubilizing or dispersing agents such as those known in the art.
[0038] Formulations for rectal administration may be presented as a suppository with a carrier such as cocoa butter, synthetic glyceride esters, or polyethylene glycol. Such carriers are typically solid at ordinary temperatures but liquefy and / or melt in the rectal cavity to release the drug.
[0039] Formulations for topical administration in the mouth (e.g., buccal or sublingual administration) include, for example, lozenges (active ingredient in a flavored base such as sucrose or acacia or tragacanth) and pastilles (active ingredient in a base such as gelatin and glycerin or sucrose and acacia). Exemplary compositions for topical administration include a topical carrier such as Plastibase (mineral oil gelled with polyethylene).
[0040] Pharmaceutical compositions suitable for oral administration can be presented as discrete units such as capsules, cachets, or tablets, each containing a predetermined amount of the active ingredient; as powders or granules; as solutions or suspensions in aqueous or non-aqueous liquids; or as oil-in-water or water-in-oil liquid emulsions. The compound of formula (I) can also be presented as a bolus, electuary, or paste. The pharmaceutical composition can optionally be in a form that provides slow or controlled release of the compound of formula (I) upon administration to a subject. Various pharmaceutically acceptable carriers and their formulations are described in standard formulation treatises, for example, Remington's Pharmaceutical Sciences by E.W. Martin. See also Wang, Y.J., and Hanson, M.A., Journal of Parenteral Science and Technology, Technical Report No. 10, Supp. 42:2S, 1988.
[0041] Preferred unit dosage compositions are those containing a probing dose or a therapeutic dose, or an appropriate fraction thereof, of a compound of Formula (I).
[0042] In a preferred embodiment, the composition for use according to the present invention consists essentially of a compound of Formula (I) and at least one pharmaceutically acceptable excipient. An exemplary composition for use according to the present invention comprises one or more pharmaceutically acceptable excipients such as crospovidone, lactose, magnesium stearate, polyvinylpyrrolidone (e.g., povidone K25), hypromellose, ethylcellulose, polyethylene glycol, talc, red iron oxide, and titanium dioxide. A further exemplary composition for use according to the present invention is a tablet having a core and a coating, wherein the core comprises crospovidone, lactose, magnesium stearate, and povidone, and the coating comprises hypromellose, polyethylene glycol, red iron oxide, and titanium dioxide.
[0043] It should be understood that in addition to the ingredients particularly mentioned above, formulations for use in the present invention may include other agents conventional in the art having regard to the type of formulation in question.
[0044] The compositions of the present invention may contain one or more additional therapeutic agents.The examples of the additional therapeutic agents that can be present in the compositions of the present invention include but are not limited to methylphenidate, amphetamine (for example, dexamphetamine), lisdexamphetamine, atomoxetine, viloxazine, clonidine and guanfacine.Usually, one or more additional therapeutic agents are psychostimulants such as amphetamine, methylphenidate and lisdexamphetamine.
[0045] Attention-Deficit / Hyperactivity Disorder (ADHD) The inventors have found that compounds of formula (I), and pharmaceutical compositions thereof, are particularly effective in reducing the symptoms of, or delaying the onset of, ADHD in subjects known to have or suspected of having ADHD, and in preventing ADHD in subjects known to be at risk of, or suspected of developing ADHD.
[0046] Thus, a compound of formula (I) for use in accordance with the present invention, or a pharmaceutical composition thereof, can be administered to a subject known or suspected to have ADHD, or known or suspected to be at risk for developing ADHD. The subject can be a human subject, e.g., a human patient. The human subject can be a child (e.g., under about 10 years of age), an adolescent (e.g., between about 10 and 19 years of age), or an adult (e.g., over about 18 to 21 years of age).
[0047] A subject known to have or suspected of having ADHD may have ADHD characterized by impulsive and hyperactive behavior without impairment in levels of attention (i.e., "impulsive / hyperactive" ADHD). Alternatively, a subject known to have or suspected of having ADHD may have ADHD characterized by impairment in levels of attention without hyperactivity or impulsivity (i.e., "inattentive" ADHD). Alternatively, a subject known to have or suspected of having ADHD may have ADHD characterized by impaired levels of attention accompanied by hyperactive and impulsive behavior (i.e., "combined" ADHD).
[0048] A subject who is known to be at risk of developing ADHD or who is suspected of having such a risk may be a subject who has a known or suspected genetic predisposition to developing ADHD, for example, the subject may have a mutation in the Latrophilin 3 (LPHN3) gene. Additional examples of genetic mutations involved in ADHD have been reported (see, for example, Faraone and Larsson, Molecular Psychiatry, 2019, 24, 562-575, which is incorporated herein by reference), including mutations in one or more of the following genes: serotonin transporter (5HTT) gene, dopamine transporter (DAT1) gene, D4 dopamine receptor (DRD4) gene, D5 dopamine receptor (DRD5) gene, serotonin 1B receptor gene (HTR1B), and synaptosome-associated protein (SNAP25) gene. Additionally, or alternatively, a subject known or suspected to be at risk for developing ADHD may be a subject who has been exposed to one or more potential environmental risk factors associated with ADHD, such as maternal pre-pregnancy obesity, pre-eclampsia, hypertension, acetaminophen exposure, and smoking during pregnancy, and childhood atopic disease.
[0049] In addition, subjects known or suspected to have ADHD, or known or suspected to be at risk for developing ADHD, may also have signs or symptoms of other conditions, such as depression, anxiety disorders, oppositional defiant disorder (ODD), conduct disorder, sleep problems (e.g., sleep onset disorder due to insomnia), autism spectrum disorder (ASD), bipolar disorder, epilepsy, Tourette's syndrome, and / or learning difficulties such as dyslexia. Typically, the subject meets the diagnostic criteria for ADHD as set forth in the Diagnostic and Statistical Manual of Mental Disorders (DSM) or the International Classification of Diseases (ICD).
[0050] In addition, subjects known or suspected to have ADHD, or known or suspected to be at risk for developing ADHD, may also suffer from a substance abuse disorder, such as addiction and / or abuse of psychostimulants such as amphetamines. For example, a compound of formula (I) for use in accordance with the present invention, or a composition thereof, may be administered to a subject for whom one or more established psychostimulant-based ADHD treatments (e.g., methylphenidate, dexamphetamine, and lisdexamphetamine) are deemed inappropriate because they are at risk of, have a history of, or currently suffer from a substance abuse disorder.
[0051] Using a zebrafish model of ADHD, the inventors have shown that compounds of formula (Ia) are surprisingly effective in reducing hyperactivity and motor impulsivity. The inventors have also shown that compounds of formula (Ia) are surprisingly effective in restoring cognitive function in a mouse model of scopolamine-induced cognitive impairment. Thus, in certain embodiments, compounds of formula (I) for use in accordance with the present invention, or pharmaceutical compositions thereof, may be administered to subjects known to or suspected of having ADHD characterized by reduced levels of attention, hyperactivity, and / or impulsive behavior (i.e., "impulsive / hyperactive" ADHD, "inattentive" ADHD, and / or "combined" ADHD).
[0052] The effectiveness of compounds of Formula (Ia) in reducing hyperactivity and motor impulsivity in zebrafish models of ADHD makes compounds of Formula (I) particularly attractive treatments for ADHD characterized by hyperactive and / or impulsive behavior (i.e., "impulsive / hyperactive" ADHD or "combined" ADHD). Accordingly, in certain embodiments, compounds of Formula (I), or pharmaceutical compositions thereof, for use in accordance with the present invention may be administered to subjects known to or suspected of having ADHD characterized by impulsive and hyperactive behavior without impaired levels of attention (i.e., "impulsive / hyperactive" ADHD), or ADHD characterized by reduced levels of attention accompanied by hyperactive and impulsive behavior (i.e., "combined" ADHD).
[0053] The efficacy of the compound of formula (Ia) in restoring cognitive function in a scopolamine-induced cognitive impairment model makes the compound of formula (I) a particularly attractive treatment for ADHD characterized by impaired levels of attention without hyperactivity or impulsivity (i.e., "inattentive" ADHD), or ADHD characterized by reduced levels of attention accompanied by hyperactivity and impulsivity (i.e., "combined" ADHD). Thus, in certain embodiments, a compound of formula (I), or a pharmaceutical composition thereof, for use according to the present invention may be administered to a subject known to or suspected of having ADHD characterized by impaired levels of attention without hyperactivity or impulsivity (i.e., "inattentive" ADHD), or ADHD characterized by reduced levels of attention accompanied by hyperactivity and impulsivity (i.e., "combined" ADHD).
[0054] The compound of formula (I) for use according to the present invention, or a composition thereof, can be administered to a subject to whom one or more established ADHD treatments (e.g., methylphenidate, dexamphetamine, lisdexamphetamine, atomoxetine, viloxazine, guanfacine, and clonidine) have not been effective in reducing one or more of the symptoms of ADHD and / or the intolerable adverse effects induced. Examples of adverse effects known to be or suspected to be caused by established ADHD treatments include sleep disturbance, loss of appetite, elevated blood pressure, stunting, disruption of circadian rhythm, and neurotoxicity.
[0055] Sleep problems, such as difficulty falling asleep, nighttime awakenings, difficulty waking in the morning, sleep-disordered breathing, excessive daytime sleepiness, and fluctuations in sleep schedules, are common in patients with ADHD, and many established treatments for ADHD have been reported to exacerbate existing sleep problems or cause sleep problems in patients.
[0056] Sleep-related adverse effects can be very difficult for patients to manage, especially over the long term, and can have a dramatic negative impact on their quality of life. Thus, sleep-related adverse effects can cause patients to discontinue treatments that have been beneficial in controlling ADHD symptoms, such as decreased levels of attention, hyperactivity, and impulsive behavior.
[0057] The present inventors have also found that in the ADHD zebrafish assay, the compound of formula (Ia) is significantly effective in reducing ADHD symptoms without affecting sleep parameters such as sleep fragmentation, sleep ratio, sleep speed, duration of wakefulness episodes and duration of sleep episodes.Therefore, the compound of formula (I) or its pharmaceutical composition may be particularly useful as a second-line treatment for patients who experience sleep-related adverse effects associated with other ADHD treatments, such as methylphenidate, dexamphetamine, lisdexamphetamine, atomoxetine, guanfacine and clonidine.Therefore, in certain embodiments, the compound of formula (I) or its pharmaceutical composition for use according to the present invention may be administered to a subject who has previously received another medication for the treatment or prevention of ADHD, and the medication has been discontinued or tapered due to sleep-related adverse events.
[0058] The ability of compounds of formula (Ia) to reduce ADHD symptoms without affecting sleep parameters also makes these compounds promising treatments for ADHD in patients with sleep problems associated with ADHD, or in patients who suffer from sleep disorders in addition to ADHD. Thus, in certain embodiments, compounds of formula (I) for use according to the present invention, or pharmaceutical compositions thereof, can be administered to subjects known or suspected to have ADHD, or known or suspected to be at risk of developing ADHD, as well as subjects known or suspected to have sleep problems or disorders.
[0059] The compounds of formula (I) and compositions thereof described herein find utility in methods of treating or preventing ADHD, said methods comprising administering compounds of formula (I) and compositions thereof to a patient known to have or suspected to have ADHD, or known to be at risk of developing ADHD or suspected to be at risk of developing ADHD.
[0060] The compounds of formula (I) also find use in the manufacture of medicaments for the treatment or prevention of ADHD. In an exemplary embodiment, the compounds of formula (I) may be used in the manufacture of medicaments for the treatment or prevention of ADHD characterized by impulsive and hyperactive behavior without impaired levels of attention (i.e., "impulsive / hyperactive" ADHD), or ADHD characterized by impaired levels of attention accompanied by hyperactive and impulsive behavior (i.e., "combined" ADHD), or ADHD characterized by impaired levels of attention without hyperactivity or impulsivity (i.e., "inattentive" ADHD). In a further exemplary embodiment, the compounds of formula (I) may be used in the manufacture of medicaments for the treatment or prevention of ADHD, wherein the medicament is intended for use in a subject who has previously received another medicament for the treatment or prevention of ADHD that has been discontinued or tapered due to a sleep-related adverse event. In a further exemplary embodiment, the compounds of Formula (I) may be used in the manufacture of a medicament for the treatment or prevention of ADHD, said medicament being for use in a subject known to have or suspected of having ADHD, or known or suspected of being at risk of developing ADHD, or also known to have or suspected of having a sleep problem or disorder.
[0061] Medication regimen The amount of a compound of formula (I) required to achieve a therapeutic effect will vary depending on the particular route of administration and the characteristics of the subject being treated, such as race, age, weight, sex, medical condition, the particular type of ADHD (e.g., "impulsive / hyperactive," "inattentive," and "combined" ADHD) and its severity, and other relevant medical and physical factors. A physician of ordinary skill can readily determine and administer the effective amount of a compound of formula (I) required to treat or prevent ADHD.
[0062] The compounds of formula (I) may be administered as a single dose daily (including several times daily), every two or three days, weekly, every two weeks, every three weeks, or every four weeks, or even more, depending on the subject and the characteristics of the ADHD being treated.
[0063] The compound of Formula (I) (excluding the mass of any counterion or solvent) can be administered in an amount of about 1 μg to 1000 μg per dose. For example, at least 1 μg, at least 5 μg, at least 10 μg, at least 15 μg, at least 20 μg, at least 25 μg, at least 40 μg, at least 50 μg, at least 60 μg, at least 70 μg, at least 80 μg, at least 90 μg, at least 100 μg, at least 110 μg, at least 120 μg, at least 130 μg, at least 140 μg, at least 150 μg, at least 200 μg, at least 300 μg, at least 400 μg, at least 500 μg, at least 600 μg, at least 700 μg, at least 800 μg, at least 900 μg, or 1000 μg can be administered to a subject.
[0064] Typically, the compound of formula (I) is administered as a single dose of 100 μg, 200 μg, 300 μg, 400 μg, 500 μg, or 600 μg (excluding the mass of any counterion or solvent). Alternatively, the compound of formula (I) is administered as a dose of 100 μg, 150 μg, 200 μg, 250 μg, or 300 μg (excluding the mass of any counterion or solvent), twice, three times, or four times a day. For example, a daily dose of 100 μg per day can be administered as two separate doses of 50 μg, with the first dose being administered in the morning and the second dose being administered in the afternoon (for example, after 6 p.m.). Or, for example, a daily dose of 200 μg per day may be administered as two separate doses of 100 μg, with the first dose administered in the morning and the second dose administered in the afternoon. Or, for example, a daily dose of 300 μg per day may be administered as two separate doses, with the first dose of 100 μg administered in the morning and the second dose of 200 μg administered in the afternoon. Or, for example, a daily dose of 400 μg per day may be administered as two separate doses, with the first dose of 200 μg administered in the morning and the second dose of 200 μg administered in the afternoon.
[0065] In certain embodiments, the compound of formula (I) is administered as a composition. Preferably, the composition is a pharmaceutical composition for use in accordance with the present invention.
[0066] Although the compound of formula (I) may be used as the sole active ingredient in the present invention, it may also be used in combination with one or more additional therapeutic interventions, and the use of such combinations provides one embodiment of the present invention. Examples of additional therapeutic interventions include pharmacological interventions, dietary interventions, and psychological interventions.
[0067] The additional pharmacological intervention can be a therapeutic agent useful for treating or preventing ADHD, or other pharmacologically active substance.Such agents are known in the art.The examples of the additional therapeutic agent for use in the present invention include those described herein.Typically, the additional therapeutic agent is a psychostimulant such as amphetamine, methylphenidate, and lisdexamfetamine.Examples of suitable dietary intervention include, for example, supplemental fatty acids and excluding artificial food dyes from diet.Examples of suitable psychological intervention include, for example, cognitive behavioral therapy (CBT).
[0068] One or more additional therapeutic interventions may be used simultaneously, sequentially, or separately with the administration of a compound of formula (I). The individual components of such combinations may be administered separately at different times during the course of therapy, or simultaneously in divided or single combination forms. An ordinarily skilled physician can readily determine and administer the effective amount of one or more therapeutic interventions required to have the desired therapeutic effect.
[0069] Preferred unit dosage compositions for use in accordance with the present invention are those containing an effective dose, or an appropriate fraction thereof, of a compound of Formula (I). Release of a compound of Formula (I) from a particular composition may also be sustained, for example, when the composition contains suitable controlled-release excipients.
[0070] kit The present invention provides kits comprising a compound of formula (I), one or more pharmaceutically acceptable excipients, and, optionally, one or more additional therapeutic agents useful for the treatment or prevention of ADHD. Examples of such additional therapeutic agents include those suitable for use in the present invention and optionally present in the pharmaceutical compositions of the present invention as additional therapeutic agents.
[0071] The kits of the present invention may also contain instructions for a suitable dietary intervention and / or instructions for a suitable psychological intervention for ADHD. For example, the kit may include instructions for a suitable nutritional plan for the subject being treated, and / or the kit may include instructions / guidance for cognitive behavioral therapy (CBT).
[0072] The kits of the present invention find use in the treatment and prevention of ADHD.
[0073] For the avoidance of doubt, the compound of formula (I) present in the kit according to the present invention is in a form and amount suitable for use according to the present invention. Suitable pharmaceutical compositions and formulations are described herein. One skilled in the art can readily determine the amount of compound of formula (I) to be included in the kit of the present invention and suitable for use according to the present invention.
[0074] equivalent The present invention has been described broadly and generically herein. Those skilled in the art will readily appreciate that all parameters, dimensions, materials, and configurations described herein are intended to be exemplary, and that the actual parameters, dimensions, materials, and / or configurations will depend on the particular application or applications for which the teachings of the present invention are used. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Accordingly, the foregoing embodiments are presented by way of example only, and it should be understood that, within the scope of the appended claims and their equivalents, the invention may be practiced otherwise than as specifically described or claimed. The present invention relates to each individual feature, system, article, material, kit, and / or method described herein. In addition, any combination of two or more such features, systems, articles, materials, kits, and / or methods is included within the scope of the invention, provided such features, systems, articles, materials, kits, and / or methods are not mutually inconsistent. Furthermore, each of the narrower species and subgeneric groupings included in the generic disclosure also form part of the invention. This includes the generic specification of the invention with a provisos or negative limitation removing any subject matter from the genus, regardless of whether the removed material is specifically described herein.
[0075] Incorporation by Reference The contents of the publications, patents, and patent applications, and all other documents and electronically available information mentioned or cited herein are incorporated by reference in their entirety to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference. Applicants reserve the right to physically incorporate into this application any and all materials and information from any such publications, patents, patent applications, or other physical and electronic documents.
[0076] The following examples illustrate the invention. [Example]
[0077] Danio rerio has gained popularity in biological psychiatry. Its rich behavioral repertoire, well-established behaviors, and availability of automated behavioral assays make it a useful model for various human brain disorders. The neural pathways involved in brain physiology are highly conserved, including all major neurotransmitter systems and high genetic homology. Gene editing techniques enable accurate modeling of human disorders. The lphn3.1 knockout model of ADHD described herein robustly exhibits features of human ADHD, namely, hyperactivity, hypersensitivity to known dopamine agonists, and phenotypic rescue following administration of known ADHD compounds.
[0078] Materials and Methods: Zebrafish larvae carrying a knockout of the Latrophilin3 (Lphn3.1) gene were generated using CRISPR-Cas9. Zebrafish were maintained in a 3L or 10L multi-tank constant-flow system (Aquatic Habitats, Apopka, FL, USA) under a 14:10 light:dark cycle. For behavioral analysis, a total of 881 6-day-postfertilization (dpf) embryos carrying a homozygous knockout of the Lphn3.1 gene were used. Adult zebrafish carrying a homozygous knockout of the Lphn3.1 gene and those with a wild-type Lphn3.1 gene were fed various diets, including TetraMin flakes (Tetra Holding GmbH, Melle, Germany) and live Artemia, three times daily. Water temperature was maintained at a constant 28.5°C and was changed at a rate of 10% per day. Eggs were collected between 10:00 AM and 12:00 AM and placed in 2-L tanks. The following day, dead eggs were removed and the tanks were cleaned. Eggs were incubated in methylene blue-mixed water at 28.5°C for 4 days. All procedures in this study were conducted in strict accordance with and approved by the National Bioethics Committee of Iceland (Regulation 460 / 2017).
[0079] Genotyping Western blot was used to validate the strains for knockdown of the Lphn3.1 gene.
[0080] Behavior Recording At 5 dpf, larvae were placed in individual wells of a 96-microwell plate (Nunc, Roskilde, Denmark) in the water system. The microwell plate was transferred to a custom-built activity monitoring system equipped with 24 infrared cameras (Ikegami, ICD-49E, Ikegami Tsushinki Co, Japan), thermostated at 28.5°C, shielded from sunlight, and illuminated from below with white light (255 lx, light phase) and infrared light (0 lx, dark phase). Larval behavior was tracked in two dimensions at 5 Hz. Larvae were left to acclimate to the activity monitoring system for 24 h before recording. Exclusion criteria were based on the percentage of samples during recording in which larvae were not tracked. A threshold of 10% was set, so larvae that were tracked for less than 90% of the total recording time were excluded from the study.
[0081] Motility assay After a 24-hour acclimation period, behavioral recordings were performed. Locomotor activity was recorded between 1:00 PM and 6:00 PM at 6 dpf during alternating light and dark conditions presented at 30-minute intervals. The mean distance traveled by larvae during this period (mm) was calculated as the average of the total swimming distance during five separate 30-minute intervals immediately following the shift to light.
[0082] Example 1: Efficacy of Moxonidine Compared to Atomoxetine in a Zebrafish Model of ADHD Zebrafish larvae with a homozygous knockout of the Lphn3.1 gene (referred to herein as "Lphn3.1 HOM") and zebrafish larvae with a wild-type Lphn3.1 gene (referred to herein as "Lphn3.1 WT") were exposed to the commercially available ADHD drug atomoxetine hydrochloride (tomoxetine hydrochloride), moxonidine (Prestwick, 67400 Illkirch, France), or vehicle control before behavioral recordings began.
[0083] Drug preparation was performed on the day of recording. Drugs were diluted from stock solutions using distilled water (Invitrogen, Paisley, PA4 9RF, UK). Three different concentrations of each drug were used: 1 μM, 10 μM, and 30 μM. In addition, a 0.03% DMSO (Sigma-Aldrich, St. Louis, USA) solution was prepared for the vehicle control group. Drugs and vehicle controls were added to the microwells between 11:30 AM and 12:30 PM on the day of recording.
[0084] Data were acquired using EthoVision XT (Version 11.5.2016, Noldus) and exported to Microsoft Excel for analysis. Statistical analysis was performed using IBM SPSS Statistics for Windows, version 26 (IBM Corp., Armonk, NY, USA). Figures were generated using Microsoft Excel and GraphPad Prism Software (Version 5.01, GraphPad Software Inc.). Data are presented as mean ± standard error of the mean (sem). For analyses of naive Lphn 3.1 larvae (i.e., untreated larvae not receiving test compound or vehicle control) and DMSO larvae (i.e., larvae receiving only DMSO vehicle control), statistical differences were assessed using two-way ANOVA. For analyses of moxonidine-treated Lphn 3.1 larvae, statistical differences were assessed using one-way ANOVA with Dunnett's two-tailed post hoc analysis. P < 0.05 was considered statistically significant.
[0085] result: After 24 hours of recording, Lphn3.1 HOM larvae were found to exhibit a pronounced hyperactivity phenotype. Higher peak velocities were observed after lights-off (which causes a typical short increase in zebrafish activity) and higher grand average velocities during the light-on period (Figure 1). In Figure 1, the activity of Lphn3.1 HOM larvae is shown by the upper line, and the activity of Lphn3.1 WT larvae is shown by the lower line. The overall activity pattern of the larvae suggested that any period could be selected for statistical analysis.
[0086] Using the average speed during the light period, we showed that, first, homozygous larvae were indeed statistically significantly more motile than wild-type larvae, and second, the vehicle (DMSO) had no effect on behavior (Fig. 2).
[0087] Both atomoxetine and moxonidine were found to increase velocity in wild-type larvae. The effects of moxonidine were compared to the optimal dose of atomoxetine (see Figure 3). Compared to Lphn3.1 HOM larvae administered vehicle control, all doses of moxonidine were found to be significantly different from the vehicle control and untreated larvae (in a dose-dependent manner). These data indicate that moxonidine is effective in reducing ADHD-like phenotypes in Lphn3.1 HOM larvae.
[0088] Furthermore, moxonidine was found to reduce the ADHD-like phenotype in Lphn3.1 HOM larvae in a specific manner, as shown by the spectrograms in Figure 5 , indicating that a 10 μM dose of moxonidine corrects the behavioral defects in Lphn3.1 HOM larvae but does not affect the behavioral parameters of wild-type larvae.
[0089] Example 2: Efficacy of moxonidine compared to donepezil and atomoxetine in models of cognitive impairment Experiments in zebrafish larvae show a significant reduction in hyperactivity after treatment with moxonidine. As ADHD further manifests itself as cognitive impairment, such as impaired attention and working memory, the effects of moxonidine were tested in cognitive assays using a scopolamine-induced cognitive impairment model in mice.
[0090] Male CD-1 mice aged 4–5 weeks were assigned to a T-maze and subjected to the T-maze alternation test as described in Andriambeloson et al., 2014 (Pharma Res Per, 2(4), 2014, e00048, incorporated herein by reference). Briefly, each mouse was placed in a T-maze consisting of a base and two arms. The experiment consisted of one "forced-choice" trial to assess the number of spontaneous alternations and 14 "free-choice" trials. One-way ANOVA revealed significant differences between groups after scopolamine exposure and treatment with the three different drugs (f = 17.08, df = 6, p < 0.0001). Dunnett's multiple comparison post-hoc test revealed a significant decrease in spontaneous alternations after scopolamine exposure compared to saline-exposed mice (p < 0.0001), confirming cognitive impairment. This effect was rescued by treatment with the acetylcholinesterase inhibitor donepezil (p<0.0001) and the known ADHD drug atomoxetine (p<0.0001). In this study, a dose-dependent significant increase in spontaneous alternation was observed for moxonidine (0.1 mg / kg, 0.3 mg / kg, and 1 mg / kg), at 0.3 mg / kg (p<0.001) and 1 mg / kg (p<0.0001), indicating a significant increase in spontaneous alternation compared to mice exposed to scopolamine (see Figure 4).
[0091] Example 3: Effects of moxonidine on sleep behavior Moxonidine has previously been shown to produce lower levels of sedation compared to other partial α2-adrenergic agonists. In particular, Tan et al. (Proc Natl Acad Sci USA. 2002 Sep 17; 99(19): 12471-6) observed that moxonidine produced less sedation compared to clonidine and brimonidine in the rotarod assay. This assay provides a measure of muscle weakness and / or motor coordination, which may occur with certain sleep states but may also occur independently of sleep. The rotarod assay does not provide a measure of sleep behavior. Therefore, to evaluate the effects of moxonidine on sleep behavior, sleep behavior in freely moving zebrafish (Lphn3.1 HOM larvae) after treatment with moxonidine, a comparator compound, or a negative control (i.e., saline or vehicle control) was assessed according to the criteria described by Levitas-Djerbi et al. (Curr Opin Neurobiol. 2017;44:89-93) and Sorribes et al. (Front Neural Circuits. 2013 Nov 13;7:178).
[0092] Briefly, sleep behavior was recorded in 96-well plates and analyzed during the lights-off period (22:00–08:00). First, all behaviors were dichotomized into 1-s bins of locomotion or non-locomotion. Previously, detailed frame-by-frame video analysis by three independent raters established a velocity of 1.0 mm / s as the threshold for locomotion in larval zebrafish. Any activity slower than that threshold was calculated as non-locomotion, thus rendering the dichotomized recordings either locomotion or non-locomotion. Next, the dichotomized recordings were converted into sleep and wake bins. According to sleep criteria previously established in adults and adapted for larval fish (Yokogawa et al., PLoS Biol. 2007;5(10):2379-97; Sorribes et al., Front Neural Circuits. 2013;7:178; and Sigurgeirsson et al., Behav Brain Res. 2013;256:377-90), six or more consecutive 1-s bins of non-movement were counted as sleep, and all others were counted as wake. That is, the seventh second and above were classified as sleep, and all other episodes were classified as wake. Once the number of sleep and wake episodes was calculated, five different sleep parameters (i.e., sleep fragmentation, sleep ratio, rate during sleep, duration of wake episodes, and duration of sleep episodes) were assessed. Sleep fragmentation was defined as the number of transitions between sleep and wake episodes per hour. Sleep ratio was calculated as the percentage of the total nighttime time during which the fish was considered asleep. Sleep velocity (mm / sec) was defined as the average velocity during the night. Wake episode duration was defined as the average length of a wake episode. Sleep episode duration was defined as the average length of a sleep episode.
[0093] result: Readings for each sleep parameter after treatment with moxonidine, clonidine, atomoxetine, or guanfacine are included below in Tables 1A-1D. [Table 1A] [Table 1B] [Table 1C] [Table 1D]
[0094] When comparing all sleep parameters, a clear contrast was observed between moxonidine and three other anti-ADHD compounds (clonidine, atomoxetine, and guanfacine): high doses of moxonidine only slightly increased speed, whereas the comparators dramatically altered all sleep parameters at most of the doses tested (see Figures 6A-6D).
[0095] Example 4: Comparison of the effects of moxonidine with those of highly selective I1-imidazoline receptor agonists in a zebrafish model of ADHD The ability of known highly selective I1-imidazoline receptor agonists to reduce ADHD-like phenotypes was evaluated and compared with moxonidine in the zebrafish model of ADHD described herein. As shown in Figure 7, known I1-imidazoline receptor agonists exhibit similar activity to moxonidine in the ADHD model, indicating that it is moxonidine's agonist activity at I1-imidazoline receptors, rather than partial activation of α2-adrenergic receptors by moxonidine, that is central to moxonidine's effects in the ADHD model.
Claims
1. A compound according to formula (I) for use in the treatment or prevention of attention deficit / hyperactivity disorder (ADHD) 【Chemistry 1】 (In the formula, R 1 , R 2 , and R 3 are independently H, halogen, C 1~4 Alkyl, C 1~4 Alkylthio-, C 1~4 alkyloxy-, and 3- to 5-membered non-aromatic carbocyclic rings, wherein the carbocyclic rings are selected from one or more C 1~4 optionally substituted with alkyl; R 4 H, C(O)H and C(O)C 1~4 alkyl, However, R 1 , R 2 , R 3 , and R 4 But not all of them are H) or a tautomer thereof, or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutically acceptable salt or solvate of the tautomer thereof.
2. R 1 is methoxy or ethoxy, and R 2 is F or Cl, and R 3 is methyl or ethyl, and R 4 2. The compound for use according to claim 1, wherein is H.
3. The compound is 【Chemistry 2】 3. The compound for use according to claim 1 or 2, which is: or a tautomer thereof, or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutically acceptable salt or solvate of the tautomer thereof.
4. 4. The compound for use according to claim 1, 2 or 3, wherein the compound is administered at a dose of about 1 μg to 1000 μg (excluding the mass of any counterion or solvent).
5. The compound for use according to any one of claims 1 to 4, wherein the compound is administered at a dose of 100µg to 600µg (excluding the mass of any counterion or solvent).
6. 6. The compound for use according to any one of claims 1 to 5, wherein the dose of the compound is administered as a single daily dose of 200 μg, 300 μg, 400 μg, 500 μg, or 600 μg (excluding the mass of any counterion or solvent).
7. 7. The compound for use according to any one of claims 1 to 6, wherein the dose of the compound is 100 μg, 150 μg, 200 μg, 250 μg, or 300 μg (excluding the mass of any counterion or solvent), administered in two, three, or four doses per day.
8. 8. The compound for use according to any one of claims 1 to 7, wherein the compound is administered simultaneously, sequentially or separately from one or more further therapeutic interventions, such as dietary, psychological and / or pharmacological interventions.
9. 9. The compound for use according to claim 8, wherein the compound is administered simultaneously, sequentially, or separately with one or more further pharmacological interventions selected from methylphenidate, dexamphetamine, lisdexamphetamine, atomoxetine, and guanfacine.
10. 9. The compound for use according to any one of claims 1 to 8, wherein the compound is administered to a subject who is previously receiving another medication for the treatment or prevention of ADHD, and the medication has been discontinued or tapered due to a sleep-related adverse event.
11. 11. The compound for use according to any one of claims 1 to 10, wherein the compound is administered to a subject known to have or suspected of having ADHD characterized by impulsive and hyperactive behavior without impairment in the level of attention (i.e., "impulsive / hyperactive" ADHD), or a subject known to have or suspected of having ADHD characterized by a reduced level of attention accompanied by hyperactive and impulsive behavior (i.e., "combined" ADHD).
12. 10. A method for the treatment or prevention of ADHD, comprising administering a dose of a compound according to claim 1, 2, or 3 to a patient known to have ADHD, suspected to have ADHD, or at risk of developing ADHD.
13. 13. The method of claim 12, wherein the patient is previously receiving another medication for the treatment or prevention of ADHD, and the medication has been discontinued or tapered due to a sleep-related adverse event.
14. 14. The method of claim 12 or 13, wherein the patient is known to have or suspected of having ADHD characterized by impulsive and hyperactive behavior without impaired levels of attention (i.e., "impulsive / hyperactive" ADHD), or is known to have or suspected of having ADHD characterized by reduced levels of attention accompanied by hyperactive and impulsive behavior (i.e., "combined" ADHD).
15. 10. Use of a compound according to claim 1, 2 or 3 for the manufacture of a medicament for the treatment or prevention of ADHD.
16. 10. A kit comprising a compound according to claim 1, 2 or 3, one or more further pharmacological interventions, instructions for dietary intervention and / or instructions for psychological intervention.
17. 17. The kit of claim 16 for use in treating or preventing ADHD.
